Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · See Remarks | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 488,182 |
Reported balance
After 2026-08-24 transaction · row 1
1 source rowRow 1 · 2026-08-24 · Sale · Disposed 13,818 · Balance 488,182 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2020 Filed Apr 23, 2020 20:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 136,000 | $0.00 Strike: $74.58 | $0.00 |
DisclosureSEC source: 0001209191-20-025440 · doc4.xml · derivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,000 Underlying: Class A Common Stock · 136,000 shares Expires 2030-04-21 F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2020 and each month thereafter, subject to the reporting person continuing as a service provider through each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-023282 · doc4.xml · derivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,300 | $59.71 | $137,328.17 |
DisclosureSEC source: 0001209191-20-023282 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.27 to $59.90. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 13,207 | $58.37 | $770,847.69 |
DisclosureSEC source: 0001209191-20-023282 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,800 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.02 to $59.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 18,243 | $57.74 | $1,053,272.38 |
DisclosureSEC source: 0001209191-20-023282 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,007 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.02 to $58.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:11 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-023282 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 33,750 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · derivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,750 Underlying: Class A Common Stock · 33,750 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F10 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,845 | $69.84 | $268,533.26 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · price: This transaction was executed in multiple trades at prices ranging from $69.53 to $70.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,099 | $69.20 | $214,448.63 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,345 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $68.52 to $69.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,300 | $67.96 | $88,343.97 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,444 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $67.50 to $68.49. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $66.73 | $133,464.00 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,744 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.35 to $67.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,816 | $65.74 | $250,847.81 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,744 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.35 to $66.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,200 | $64.85 | $402,063.80 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,560 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.34 to $65.29. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,702 | $63.78 | $555,050.98 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,760 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.335 to $64.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,788 | $62.88 | $301,060.34 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,462 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.31 to $63.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:45 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 33,750 | $0.88 | $29,700.00 |
DisclosureSEC source: 0001209191-20-017553 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 00:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-20-002150 · doc4.xml · derivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,500 Underlying: Class A Common Stock · 67,500 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 00:33 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 67,500 | $0.88 | $59,400.00 |
DisclosureSEC source: 0001209191-20-002150 · doc4.xml · nonDerivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 12 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Class A Common Stock · 100,000 shares Expires 2029-05-10 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F7 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 11 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 100,000 shares Expires 2029-05-10 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F7 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 10 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Class A Common Stock · 175,000 shares Expires 2028-11-02 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F6 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 9 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 175,000 shares Expires 2028-11-02 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F6 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 8 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Class A Common Stock · 200,000 shares Expires 2027-10-18 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F5 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 7 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 200,000 shares Expires 2027-10-18 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F5 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 6 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Class A Common Stock · 125,000 shares Expires 2026-11-18 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on August 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 5 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 125,000 shares Expires 2026-11-18 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on August 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 4 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Class A Common Stock · 450,000 shares Expires 2025-10-27 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F3 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 3 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 450,000 shares Expires 2025-10-27 F2 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F3 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. F2 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass B Common Stock · Derivative | 3,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 2 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Class A Common Stock · 3,000,000 shares Expires not disclosed F1 · security: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherClass A Common Stock · Derivative | 3,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-023631 · doc4.xml · derivative · entry 1 Hindson Benjamin J. · CIK 0001786391 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 3,000,000 shares Expires not disclosed F1 · security: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.exercise_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.expiration_date: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class A Common Stock was reclassified into one share of Class B Common Stock immediately prior to the completion of the Issuer's initial public offering. Each share of Class B Common Stock is convertible at any time at the option of the Reporting Person into one share of Class A Common Stock and has no expiration date. Additionally, each share of Class B Common Stock will convert automatically into one share of Class A Common Stock upon transfer, whether or not for value (subject to certain exceptions) and upon the occurrence of certain other events set forth in the Issuer's Amended and Restated Certificate of Incorporation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.